• 1
    Lamm DL, Reichert DF, Harris SC, Lucio RM. Immunotherapy of transitional cell carcinoma. J. Urol. 1982; 128: 11048.
  • 2
    Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. Cancer 1995; 75: 5529.
  • 3
    Ratliff TL. Role of the immune response in BCG for bladder cancer. Eur. Urol. 1992; 21 (Suppl. 2): 1721.
  • 4
    Zbar B, Rapp WJ. Immunotherapy of guinea pig cancer with BCG. Cancer 1974; 30: 153240.
  • 5
    Ratliff TL, Palmer JO, McGarr JA, Brown EJ. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. Cancer Res. 1987; 47: 176276.
  • 6
    Akaza H, Iwasaki A, Ohtani M et al. Expression of antitumor response. Role of attachment and viability of Bacillus Calmette-Guérin to bladder cancer cells. Cancer 1993; 72: 55863.
  • 7
    Ikeda N, Toida I, Yamada H, Iwasaki A, Akaza H. Interaction of Bacillus Calmette-Guérin (BCG) with bladder tumor cells. Biotherapy 1996; 10: 87984.
  • 8
    El-Demiry MIM, Smith G, Ritchie AWS et al. Local immune responses after intravesical BCG treatment for carcinoma in situ. Br. J. Urol. 1987; 60: 5438.
  • 9
    Prescott L, James K, Busuttil A, Hargreave TB, Chishom GK, Smyth JF. HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br. J. Urol. 1989; 63: 2649.
  • 10
    Stefanin GF, Bercovich E, Mazzeo V et al. Class I and class II HLA antigen expression by transitional cell carcinoma of the bladder: Correlation with T-cell infiltration and BCG treatment. J. Urol. 1989; 141: 144953.
  • 11
    Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local Bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J. Urol. 1990; 144: 538.
  • 12
    Hawkyard K, James K, Prescott S et al. The effects of recombinant human interferon gamma on a panel of human bladder cancer cell lines. J. Urol. 1991; 145: 107881.
  • 13
    Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of Vα14 NK T-cells by glycosylceramides. Science 1997; 278: 16269.
  • 14
    Leschow DJ, Walunas TL, Blaueston JA. CD28/B7 system of T-cell costimulation. Ann. Rev. Immunol. 1996; 14: 23358.
  • 15
    Makgoba MW, Sanders ME, Luice GEG et al. Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1 dependent adhesion in T cell-mediated cytotoxicity. Eur. J. Immunol. 1988; 18: 63740.
  • 16
    Isobe M, Yazaki Y. Adhesion of T cells and antigen presenting cells. Mebio 1993; 10: 739.
  • 17
    Tomita Y, Watanabe H, Kobayashi H et al. Expression of intercellular adhesion molecule-1 on transitional cell cancer. Possible significance in immunity against tumor cells. Am. J. Path. 1993; 143: 1918.
  • 18
    Campbell SC, Tanabe K, Alexander JP, Edinger M, Tubbs RR, Klein RR. Intercellular adhesion molecule-1 expression by bladder cancer cells: Functional effects. J. Urol. 1994; 151: 138590.
  • 19
    Stingl G, Tamaki K, Katz SI. Origin and function of epidermal Langerhans cells. Immunol. Rev. 1980; 53: 14974.
  • 20
    Stephen M, Breathnach MA, Shimada S, Kovac Z, Stephen IK. Immunologic aspects of acute cutaneous graft-versus-host disease: Decreased density and antigen presenting function of Ia+ Langerhans cells and absent antigen-presenting capacity of Ia+ keratinocytes. J. Invest. Dermatol. 1986; 86: 22634.
  • 21
    Kakiuch T, Chesnut RW, Grey HM. B cells as antigen-presenting cells: The requirement for B cell activation. J. Immunol. 1983; 131: 10914.
  • 22
    Pawelec G, Blaurock M, Schneider EM, Shaw S, Wernet P. Alloactivated long-term cultured human T lymphocyte stimulation capacity. Eur. J. Immunol. 1982; 12: 96772.
  • 23
    Epperson DA, Pober JS. Antigen-presenting function of human endothelial cells. Direct activation of resting CD8+ T cells. J. Immunol. 1994; 153: 540212.
  • 24
    Martin-Villa JM, Ferre-Lopez S, Lopez-Suarez JC, Corell A, Perez-Blas M, Arnaiz-Villena A. Cell surface phenotype and ultramicroscopic analysis of purified human enterocytes: A possible antigen-presenting cell in the intestine. Tissue Antigens 1997; 50: 58692.
  • 25
    Housseau F, Rouas-Freiss N, Roy M, Bidart JM, Guillet JG, Bellet D. Antigen-presenting function of murine gonadal epithelial cell lines. Cell Immunol. 1997; 177: 93101.
  • 26
    Lattime EC, Gomella LG, McCue PA. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res. 1992; 52: 428690.
  • 27
    Stephen PS, Liesbeth EJ, Rob RJM et al. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res. 1998; 58: 3094100.